Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-06-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
国浩律师（杭州）事务所关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm (国浩律师（杭州）事务所) regarding 奥锐特药业股份有限公司's issuance of convertible corporate bonds to unspecified investors. It includes extensive legal analysis, references to relevant laws and regulations (e.g., Company Law, Securities Law, Management Measures), descriptions of the issuer's qualifications, approvals, authorizations, and compliance with issuance conditions. The document is lengthy (15,000 characters) and contains substantive content rather than a brief announcement or certification. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital market transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as bond issuance. Therefore, the appropriate classification is CAP with high confidence.
2023-06-30 Chinese
奥锐特药业股份有限公司关于全资子公司通过药品GMP符合性检查的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company's board regarding the passing of a GMP (Good Manufacturing Practice) compliance inspection for a wholly owned subsidiary's production line. It details the inspection scope, results, and some market context for the product involved. The document is relatively short (1067 characters) and serves as a regulatory announcement about compliance and operational status rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance changes. It is not a report publication announcement since it contains substantive information about the inspection result. The content fits best under Regulatory Filings (RNS) as it is a regulatory compliance announcement that does not fit other specific categories like Annual Report, Earnings Release, or Management Reports.
2023-06-29 Chinese
奥锐特药业股份有限公司关于公司获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration (国家药品监督管理局). It details the drug's registration information, market context, company investment in the drug's development, and potential impact and risks. The document is relatively short (1223 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it is the announcement itself, not a notice about a report release. The content fits best under a general regulatory announcement category, as it informs investors and the public about a significant regulatory milestone affecting the company. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-06-26 Chinese
奥锐特药业股份有限公司2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2022 annual dividend distribution by 奥锐特药业股份有限公司. It details the dividend per share, relevant dates for dividend distribution, tax withholding policies, and shareholder meeting approval. The document is short (2180 characters) and focuses solely on dividend distribution details without containing full financial statements or comprehensive annual report content. This fits the definition of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release. Therefore, the correct classification is DIV.
2023-05-15 Chinese
奥锐特药业股份有限公司独立董事关于第三届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding matters discussed at the first meeting of the third board of directors. It includes opinions on the appointment of senior management and changes in accounting policies. The content focuses on board/management decisions and approvals rather than financial results or regulatory filings. The document is relatively short (855 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results or a proxy statement. Therefore, the document best fits the category of Board/Management Information (MANG), as it relates to board decisions and management appointments.
2023-05-08 Chinese
奥锐特药业股份有限公司第三届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the first meeting of the third board of directors of 奥锐特药业股份有限公司, including election of chairman, vice chairman, committee members, appointment of senior management, and approval of accounting policy changes. It contains no financial statements or detailed financial data, but rather governance and management changes. The document also references previous announcements for detailed biographies and related disclosures. The content fits the category of Board/Management Information (MANG) as it reports changes in the company's board and senior management.
2023-05-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.